Jimin Hong

Jimin Hong

Auto-generated profile, based on publicly available information

Jimin Hong

Department of Nuclear Medicine, University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021
Verified
Conference Paper
Open access
PDF file
JHJimin Hong
Jimin Hong
TKTaeHee Kim
TaeHee Kim
HLHyesu Lim
Hyesu Lim
JCJaeyul Choo
Jaeyul Choo
Jimin Hong, TaeHee Kim, Hyesu Lim, Jaegul Choo. Proceedings of the 2021 Conference on Empirical Methods in Natural Language Processing. 2021.

13 October 2023 in EBioMedicine
Verified
Journal Article
Open access
JHJimin Hong
Jimin Hong
JLJiaying Lu
Jiaying Lu
FLFengtao Liu
Fengtao Liu
MWMin Wang
Min Wang
XLXinyi Li
Xinyi Li
ZJZizhao Ju
Zizhao Ju
Progressive supranuclear palsy (PSP) is a primary 4-repeat tauopathy with diverse clinical phenotypes. Previous post-mortem studies examined tau deposition sequences in PSP, but in vivo scrutiny is lacking. We conducted [18F]Florzolotau tau positron emission tomography (PET) scans on 148 patients who were clinically diagnosed with PSP and 20 healthy controls. We employed the Subtype and Stage Inference (SuStaIn) algorithm to identify PSP subtype/stage and related tau patterns, comparing clinical features across subtypes and assessing PSP stage-clinical severity association. We also evaluated functional connectivity differences among subtypes through resting-state functional magnetic resonance imaging. We identified two distinct subtypes of PSP: Subtype1 and Subtype2. Subtype1 typically exhibits a sequential progression of the disease, starting from subcortical and gradually moving to cortical regions. Conversely, Subtype2 is characterized by an early, simultaneous onset in both regions. Interestingly, once the disease is initiated, Subtype1 tends to spread more rapidly within each region compared to Subtype2. Individuals categorized as Subtype2 are generally older and exhibit less severe dysfunctions in areas such as cognition, bulbar, limb motor, and general motor functions compared to those with Subtype1. Moreover, they have a more favorable prognosis in terms of limb motor function. We found significant correlations between several clinical variables and the identified PSP SuStaIn stages. Furthermore, Subtype2 displayed a remarkable reduction in functional connectivity compared to Subtype1. We present the evidence of distinct in vivo spatiotemporal tau trajectories in PSP. Our findings can contribute to precision medicine advancements for PSP. This work was supported by grants from the National Natural Science Foundation of China (number 82272039, 81971641, 82021002, and 92249302); Swiss National Science Foundation (number 188350); the STI2030-Major Project of China (number 2022ZD0211600); the Clinical Research Plan of Shanghai Hospital Development Center of China (number SHDC2020CR1038B); and the National Key R&D Program of China (number 2022YFC2009902, 2022YFC2009900), the China Scholarship Council (number 202006100181); the Deutsche Forschungsgemeinschaft (DFG) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy, ID 390857198).

28 February 2022 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
JHJimin Hong
Jimin Hong
SKSeung Kwan Kang
Seung Kwan Kang
IAIan Alberts
Ian Alberts
JLJiaying Lu
Jiaying Lu
RSRaphael Sznitman
Raphael Sznitman
TIThe Alzheimer’s Disease Neuroimaging Initiative
The Alzheimer’s Disease Neuroimaging Initiative
Purpose: Alzheimer’s disease (AD) studies revealed that abnormal deposition of tau spreads in a specific spatial pattern, namely Braak stage. However, Braak staging is based on post mortem brains, each of which represents the cross section of the tau trajectory in disease progression, and numerous studies were reported that do not conform to that model. This study thus aimed to identify the tau trajectory and quantify the tau progression in a data-driven approach with the continuous latent space learned by variational autoencoder (VAE). Methods: A total of 1080 [18F]Flortaucipir brain positron emission tomography (PET) images were collected from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. VAE was built to compress the hidden features from tau images in latent space. Hierarchical agglomerative clustering and minimum spanning tree (MST) were applied to organize the features and calibrate them to the tau progression, thus deriving pseudo-time. The image-level tau trajectory was inferred by continuously sampling across the calibrated latent features. We assessed the pseudo-time with regard to tau standardized uptake value ratio (SUVr) in AD-vulnerable regions, amyloid deposit, glucose metabolism, cognitive scores, and clinical diagnosis. Results: We identified four clusters that plausibly capture certain stages of AD and organized the clusters in the latent space. The inferred tau trajectory agreed with the Braak staging. According to the derived pseudo-time, tau first deposits in the parahippocampal and amygdala, and then spreads to the fusiform, inferior temporal lobe, and posterior cingulate. Prior to the regional tau deposition, amyloid accumulates first. Conclusion: The spatiotemporal trajectory of tau progression inferred in this study was consistent with Braak staging. The profile of other biomarkers in disease progression agreed well with previous findings. We addressed that this approach additionally has the potential to quantify tau progression as a continuous variable by taking a whole-brain tau image into account.

7 March 2023 in IEEE Transactions on Radiation and Plasma Medical Sciences
Verified
Journal Article
Open access
JHJimin Hong
Jimin Hong
MBMatthias Brendel
Matthias Brendel
KEKjell Erlandsson
Kjell Erlandsson
HSHasan Sari
Hasan Sari
JLJiaying Lu
Jiaying Lu
KSKuangyu Shi
Kuangyu Shi
In dynamic brain positron emission tomography (PET) studies, acquiring a time series of images, typically lasting more than an hour, is necessary to derive pharmacokinetic parameters. Analytically, these parameters are estimated by establishing kinetic models such as compartment models that consist of sets of ordinary differential equations (ODE), and by fitting the sparse time-activity curve (TAC) of the tracer. Yet, these models are simplified approximations of highly complex underlying processes, and sufficient samples of TAC are required throughout the entire acquisition, which is not only impractical but also hindered by patient involuntary motion and intrinsic noise. Therefore, recovering samples in missing timeframes is often required, which, in practice, is achieved by interpolation or extrapolation. Here, we introduce a novel deep-learning-based method that utilizes neural ODE (N-ODE) to predict TAC in the extended timeframes by mimicking analytical method in a data-driven manner. By training N-ODE to solve and fit sets of ODE such that the solution replicates the observed TAC, the N-ODE converges to the functional shapes that best describe the underlying pharmacokinetic processes. We customized N-ODE to predict the full-dynamic images (12 frames, 60min), hence pharmacokinetic parameters, given limited early-frame images (7 to 9 frames, 20 to 30min). For proof of concept, the proposed N-ODE was applied to simulated and clinical 18F-PI-2620 brain PET. We demonstrated that the proposed N-ODE delivered promising performance, indicated by bias, variance, and mean absolute error as well as pharmacokinetic parameters such as rate constants, standardized uptake value ratio (SUVr), and binding potential (BPND).

26 November 2024 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LCLara Cavinato
Lara Cavinato
JHJimin Hong
Jimin Hong
MWMartin Wartenberg
Martin Wartenberg
SRStefan Reinhard
Stefan Reinhard
RSRobert Seifert
Robert Seifert
KSKuangyu Shi
Kuangyu Shi

9 September 2021 in Research Square
Verified
Preprint
Open access
PDF file
JHJimin Hong
Jimin Hong
SKSeung Kwan Kang
Seung Kwan Kang
IAIan Alberts
Ian Alberts
JLJiaying Lu
Jiaying Lu
RSRaphael Sznitman
Raphael Sznitman
KSKuangyu Shi
Kuangyu Shi
PurposeAlzheimer’s disease (AD) studies revealed that abnormal deposition of tau spreads in a specific spatial pattern, namely Braak stage. However, Braak staging is based on post mortem brains, each of which represents the cross-section of the tau trajectory in disease progression, and numerous studies were reported that does not conform to this model. This study aimed to identify the tau trajectory and additionally quantify the tau progress in a data-driven approach using the continuous latent space learned by variational autoencoder (VAE). Methods1080 [18F]Flortaucipir brain PET images were collected from Alzheimer’s Disease Neuroimaging Initiative database. VAE was built to compress the hidden features from tau images in latent space. Hierarchical clustering and minimum spanning tree were applied to organize the features and calibrate them to the tau progression, thus deriving pseudo-time. The image-level tau trajectory was inferred by continuously sampling across the calibrated latent features. We assessed the pseudo-time with regards to tau standardized uptake value ratio (SUVr) in AD-vulnerable regions, amyloid deposit, glucose metabolism, cognitive scores and clinical diagnosis. ResultsWe identified 4 clusters that plausibly capture certain stages of AD and organized the clusters in the latent space. The inferred tau trajectory agreed with the Braak staging. According to the derived pseudo-time, tau first deposits in the parahippocampal and amygdala, and then spreads to fusiform, inferior temporal lobe, and posterior cingulate. Prior to the regional tau deposition, amyloid accumulates first. ConclusionThe spatiotemporal trajectory of tau progression inferred in this study was consistent with Braak staging, and the profile of other biomarkers in disease progression agreed well with previous findings. We addressed that this approach additionally carries a potential to quantify tau progression as a continuous variable taking a whole-brain tau image into account.